Overview Sierra Medical is at the forefront of early detection of lung cancer by creating AIR-DS, a non-invasive early detection test. This innovative approach aims to significantly enhance the early identification of lung cancer, potentially catching it at its most treatable stages through a simple cheek swab.

How it works The effectiveness of AIR-DS stems from its ability to identify small biochemical changes in cells from the inner cheek. These biochemical changes can serve as early indicators of lung cancer. The procedure involves taking a cheek swab, which is then analysed using non-damaging infrared light technology.

The RADICAL REACT study To introduce this technology into a healthcare setting the sponsor needs to validate its effectiveness through rigorous testing.

The RADICAL REACT trial plans to involve around 450 participants highly suspected to have lung cancer. Each participant will provide a cheek swab and basic medical history information during a single clinic visit. The data collected will be analysed with AIR-DS to identify whether individuals with lung cancer can be identified accurately.

Why it matters AIR-DS could significantly advance lung cancer detection, focusing on early, accurate diagnosis through a non-invasive cheek swab. Beyond improving patient outcomes by enabling timely intervention, it also introduces a cost-effective approach to early lung cancer detection. AIR-DS aims to alleviate the financial burden on healthcare systems and patients by reducing the need for more expensive and/or invasive diagnostic procedures.

Inclusion Criteria:

To be eligible to participate in this study, study participants must meet all the following criteria:

• Can understand and provide signed consent.
• Are aged 18 years or older.
• Can provide a cheek swab sample.
• Are symptomatic of, and/or are being investigated for, lung cancer.
• Have not commenced treatment for lung cancer.

Exclusion Criteria:

Study participants who meet any of the following criteria will be excluded from participation in this study:

• Are pregnant.

• Have been diagnosed with another known malignancy within five years (excluding localised squamous cell carcinoma of the skin, cervical intraepithelial neoplasia, grade III and low-grade prostate cancer (Gleason score <5 with no metastases)).

• Have a concurrent disease, medical condition, or extenuating circumstances that, in the opinion of the investigator, might compromise study completion or data collection, including:

  1. Localised oral disease, including but not limited to periodontitis, bleeding gums, dysplastic mouth disease.
  2. Taking anti-coagulants.
  3. Alpha 1 anti-trypsin deficiency.
  4. Active infections such as tuberculosis.
  5. Conditions that in the opinion of the investigator are not controlled e.g. hypertension, asthma, chronic kidney disease, bowel disease, etc.

Up to 450 participants will be recruited into the study from at risk or symptomatic patients being evaluated for lung cancer. The study aims to recruit approximately 196 participants with lung cancer. Recruitment will be continually monitored and may be stopped earlier than planned if the investigators have recruited 196 participants with lung cancer and with a sufficient proportion of early-stage lung cancer.

Participants who withdraw or are deemed a screen failure will be replaced and will not count towards the overall recruitment.

To be decided